Deciphering the contributions of fecal microbiota from patients with high-grade glioma to tumor development in a humanized microbiome mouse model of gliomaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study tested whether gut microbiota from glioma patients can drive brain tumor progression. Researchers combined a human cohort with a humanized-microbiome mouse model of glioma. They profiled patient and control stool by 16S rDNA amplicon sequencing. They then transplanted human fecal microbiota into antibiotic-treated mice, implanted human glioma cells intracranially, and tracked tumor growth by bioluminescence imaging. Untargeted plasma metabolomics and Spearman correlation analysis linked specific microbes to circulating metabolites. The aim was to see whether microbiota influence glioma through metabolites entering the bloodstream.
Who was studied?
The human cohort was a nested case-control study of 52 participants recruited at Zhujiang Hospital of Southern Medical University, China, between April 2022 and July 2023. It included 30 glioma patients and 22 healthy controls. The animal model used six-week-old female BALB/c-nude mice. After an antibiotic regimen, mice were assigned to receive fecal transplants from high-grade glioma patients, low-grade glioma patients, or healthy controls. Mice then received intracranial U87-Luc human glioma cells. Tumors were monitored for 12 days before tissue collection.
What were the most important findings?
Gut microbiota composition and diversity differed significantly between glioma patients and healthy controls, with conditional pathogens enriched in patients. Mice given high-grade glioma microbiota showed significantly faster tumor progression than mice given healthy-control microbiota, at day 12 with p below 0.001. Plasma metabolomics identified 1577 differentially abundant metabolites between the two mouse groups. Sphingolipid metabolism was upregulated in high-grade recipients, with elevated sphingosine and sphingosine 1-phosphate. A strictly anaerobic, Gram-positive genus enriched in high-grade recipients correlated positively with sphingosine, sphingosine 1-phosphate, and D-sphingosine. Healthy-control microbiota correlated with stearidonic acid and eicosapentaenoic acid.
What are the greatest implications of this study?
The work suggests gut microbiota from high-grade glioma patients can promote tumor growth, possibly through the metabolite sphingosine 1-phosphate reaching the bloodstream. This offers a candidate mechanism linking the gut to brain tumor progression. The correlational nature of the metabolite analysis means causation is not proven. The proposed role of the enriched gut genus and sphingosine 1-phosphate remains a hypothesis requiring direct testing. Limitations included mixed glioma grades in the human samples, high mouse mortality, small replicate numbers, and no human metabolomic cross-validation. The authors call for larger, mechanism-focused studies.